Cidara Thera (CDTX)

May 25, 2025, 9:26 PM EDT - 11 days ago

Cidara Therapeutics: All Stars Aligning In Favor Of CD388

May 15, 2025, 8:00 AM EDT - 22 days ago

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

May 13, 2025, 8:00 AM EDT - 24 days ago

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

May 10, 2025, 9:29 PM EDT - 26 days ago

Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 4 weeks ago

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 5, 2025, 5:00 AM EDT - 4 weeks ago

Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate

May 1, 2025, 8:00 AM EDT - 5 weeks ago

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Apr 30, 2025, 8:00 AM EDT - 5 weeks ago

Cidara Therapeutics to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 6 weeks ago

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Apr 16, 2025, 8:00 AM EDT - 7 weeks ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

PHAT

Apr 1, 2025, 4:56 PM EDT - 2 months ago

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Apr 1, 2025, 4:05 PM EDT - 2 months ago

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 8:00 AM EDT - 2 months ago

Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

Mar 18, 2025, 8:00 AM EDT - 2 months ago

Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

Mar 17, 2025, 6:00 AM EDT - 2 months ago

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology

Mar 6, 2025, 4:35 PM EST - 3 months ago

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 4:15 PM EST - 3 months ago

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

Feb 11, 2025, 8:22 AM EST - 4 months ago

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Jan 30, 2025, 4:05 PM EST - 4 months ago

Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Nov 21, 2024, 3:12 PM EST - 7 months ago

Cidara: Potential To Change Flu Prophylaxis Landscape With CD388

Nov 21, 2024, 8:30 AM EST - 7 months ago

Cidara Therapeutics Announces $105 Million Private Placement

Nov 19, 2024, 8:00 AM EST - 7 months ago

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

Nov 7, 2024, 4:15 PM EST - 7 months ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 7 months ago

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

Sep 25, 2024, 8:00 AM EDT - 9 months ago

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

Sep 23, 2024, 8:00 AM EDT - 9 months ago

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

Sep 19, 2024, 8:00 AM EDT - 9 months ago

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

Sep 12, 2024, 4:05 PM EDT - 9 months ago

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

Sep 5, 2024, 8:00 AM EDT - 9 months ago

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 5:12 PM EDT - 10 months ago

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

Aug 13, 2024, 4:29 PM EDT - 10 months ago

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 3, 2024, 1:05 PM EDT - 1 year ago

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2024, 8:00 AM EDT - 1 year ago

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

May 15, 2024, 4:20 PM EDT - 1 year ago

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:01 PM EDT - 1 year ago

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Apr 26, 2024, 6:01 PM EDT - 1 year ago

Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform

Apr 26, 2024, 8:00 AM EDT - 1 year ago

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

Apr 24, 2024, 7:19 PM EDT - 1 year ago

Cidara Therapeutics shares surge 30% after reacquiring flu treatment

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Apr 22, 2024, 5:10 PM EDT - 1 year ago

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Apr 22, 2024, 5:06 PM EDT - 1 year ago

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

Apr 22, 2024, 8:49 AM EDT - 1 year ago

Cidara Therapeutics Announces Reverse Stock Split

Apr 5, 2024, 3:00 PM EDT - 1 year ago

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 6, 2024, 8:00 AM EST - 1 year ago

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Jan 29, 2024, 4:30 PM EST - 1 year ago

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Dec 22, 2023, 7:30 AM EST - 1 year ago

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

Dec 7, 2023, 8:00 AM EST - 1 year ago

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Dec 6, 2023, 8:00 AM EST - 1 year ago

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China